Feugiat nulla facilisis at vero eros et curt accumsan et iusto odio dignissim qui blandit praesent luptatum zzril.
+ (123) 1800-453-1546

Related Posts

Increasing Levels of Pretreatment HIV Drug Resistance and Safety Concerns for Dolutegravir Use In Women of Reproductive Age

September 1, 2019

Seth Inzaule; Michael Jordan; Amandine Cournil; Marco Vitoria; Giovanni Ravasi; Fatim Cham; Linh-Vi Le; Janet Dzangare; Ndapewa Hamunime; Nicholus Mutenda; Avelin Aghokeng; Annez Bissek; Serge Billong; Pontiano Kaleebu; Meg Doherty; Silvia Bertagnolio;

AIDS. 2019 Sep 1;33(11):1797-1799.
PMID: 31149946 | DOI: 10.1097/QAD.0000000000002277



Use of dolutegravir-based first-line antiretroviral therapy (ART) in response to rising levels of pretreatment HIVdrug resistance (PDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) may be limited, given safetyconcerns for birth defects in women of child-bearing potential. Pooled data from 11 nationally representative surveys show that NNRTI PDR in women is nearly twice that in men, exceeding 10% in 8 of 11 countries monitored, suggesting the urgent need for a non-NNRTI-based ART regimen in this population.


Source: https://www.ncbi.nlm.nih.gov/pubmed/?term=Increasing+levels+of+pretreatment+HIV+drug+resistance+and+safety+concerns+for+dolutegravir+use+in+women+of+reproductive+age